BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bellantoni AJ, Wagner LM. Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors. Cancers (Basel) 2021;13:3531. [PMID: 34298746 DOI: 10.3390/cancers13143531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Moshe Halamish H, Zlotver I, Sosnik A. Polymeric nanoparticles surface-complexed with boric acid actively target solid tumors overexpressing sialic acid. J Colloid Interface Sci 2022;626:916-29. [PMID: 35835042 DOI: 10.1016/j.jcis.2022.07.027] [Reference Citation Analysis]
2 Ghasemi DR, Fleischhack G, Milde T, Pajtler KW. The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma. Cancers (Basel) 2022;14:679. [PMID: 35158947 DOI: 10.3390/cancers14030679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Musumeci F, Cianciusi A, D'Agostino I, Grossi G, Carbone A, Schenone S. Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma. Molecules 2021;26:7069. [PMID: 34885651 DOI: 10.3390/molecules26237069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Hua H, Zhang H, Chen J, Wang J, Liu J, Jiang Y. Targeting Akt in cancer for precision therapy. J Hematol Oncol 2021;14:128. [PMID: 34419139 DOI: 10.1186/s13045-021-01137-8] [Cited by in F6Publishing: 17] [Reference Citation Analysis]